AbbVie Inc (0QCV)
London Stock Exchange · UK · prices in USD · close of 27 Oct 2026
Key indicators
| Last close | USD 286.00 |
|---|---|
| 52-week range | 186.49 – 292.50 |
| Return, 1 month / 3 months | +8.9% / +11.2% |
| Return, 1 year / 3 years | +29.6% / +131.0% |
| Trend | Uptrend |
| RSI (14) | 65 |
| Volatility (1 year) | 26.2% |
| Worst drawdown (1 year) | -15.6% |
| Average daily value traded | 3.41M USD |
| Dividend yield | 2.4% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
AbbVie is a pharmaceutical company that develops and markets prescription medicines for chronic and serious conditions. Its products include treatments for immune and inflammatory diseases, blood cancers, neurological disorders and eye conditions, along with aesthetic treatments such as botulinum toxin and facial fillers. It serves patients, physicians and health systems, and it is based in North Chicago, Illinois, in the United States.
The shares are listed on the London Stock Exchange in UK under the code 0QCV, and the price on this page is in US dollars (USD). Our dividend records, which start in 2019, show payments in 8 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
AbbVie Inc (0QCV) trades on the London Stock Exchange in UK. It last closed at USD 286.00 on 27 October 2026.
Its price-based Market X-Ray is 76 out of 100 (a strong price profile), ranking 201 of 3,788 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 29.6% and over the last three months it rose 11.2%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Stock Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 91 · Strong | Trading above its long-term averages and near its highs. | |
| Above 200-day average | 22.8% | ||
| From 52-week high | -0.3% | ||
| Momentum | 81 · Strong | Rising faster than most stocks on this exchange. | |
| 3-month return | 11.2% | ||
| 6-month return | 46.5% | ||
| 12-month return, skipping the last month | 19.0% | ||
| Stability (higher is calmer) | 79 · Strong | Calmer than most: low volatility and shallow drawdowns. | |
| Volatility, 1 year (lower is calmer) | 26.2% | ||
| Worst drawdown, 1 year (smaller is calmer) | -15.6% | ||
| Liquidity | 64 · Fair | Moderate trading activity. | |
| Average daily value traded | 3.41M USD | ||
| Zero-volume days | 0.0% | ||
| Income | 41 · Weak | Dividend is small or irregular. | |
| Dividend yield | 2.4% | ||
| Years with dividends | 5 |
Strengths
- Trend: Trading above its long-term averages and near its highs.
- Momentum: Rising faster than most stocks on this exchange.
- Stability (higher is calmer): Calmer than most: low volatility and shallow drawdowns.
Weak spots
- Income: Dividend is small or irregular.
Returns
| 1 week | +0.4% |
|---|---|
| 1 month | +8.9% |
| 3 months | +11.2% |
| 6 months | +46.5% |
| 1 year | +29.6% |
| 3 years | +131.0% |
| 5 years | +214.8% |
Signals
| 50-day / 200-day average | 265.96 / 232.95 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | Yes |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 7.26 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 14 Oct 2026 | USD 1.7300 |
| 14 Jul 2026 | USD 1.7300 |
| 14 Apr 2026 | USD 1.7300 |
| 15 Jan 2026 | USD 1.7300 |
| 14 Oct 2025 | USD 1.6400 |
| 14 Jul 2025 | USD 1.6400 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Stock Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.